Background Targeted therapies improve survival in metastatic renal cell carcinoma (mRCC).
However, survival patterns can be divergent, and patients at the 2 extremes of the survival …

Purpose We evaluated the value of metastasectomy in patients treated with targeted therapy
for metastatic renal cell carcinoma (mRCC). Methods The medical records of 325 patients …

Aim: This retrospective study evaluates whether metastatic sites were associated with
progression-free survival (PFS) and overall survival (OS) in patients with renal cell …

Background: This retrospective register study assessed overall survival (OS) and influential
factors on OS in Swedish renal cell carcinoma (RCC) patients. Methods: Using three merged …

Although new treatments can prolong progression-free and overall survival in patients with
renal cell carcinoma (RCC), the cure rate remains low and surgical resection of the primary …

Targeted therapies are the standard treatment for mRCC. Despite advancements in survival,
progression-free survival and tolerability, these targeted therapies remain largely …

The article presents information on therapeutic approaches to metastatic renal cell
carcinoma, which comprise many methods that can only be adapted to the patient's situation …

Since the introduction of molecular targeted agents for the treatment of metastatic renal cell
cancer (mRCC), several treatment outcomes, including those from our facilities, have been …

Background This population-wide retrospective, non-interventional registry study assessed
changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal …

Purpose To describe survival in previously treated patients with metastatic renal cell
carcinoma (RCC) who are candidates for clinical trials of new agents as second-line …